The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma: Genomic, neoantigen, and immunohistochemical evaluation.
 
Diana Miao
No Relationships to Disclose
 
Dennis Adeegbe
No Relationships to Disclose
 
Scott J. Rodig
Honoraria - Bristol-Myers Squibb; Perkin Elmer
Consulting or Advisory Role - AstraZeneca; Perkin Elmer
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Patent pending for use of Anti-galectin1 antibodies for diagnostic use.
Travel, Accommodations, Expenses - Roche
 
Sachet Shukla
Consulting or Advisory Role - Neon Therapeutics
Patents, Royalties, Other Intellectual Property - Broad Institute; Dana-Farber Cancer Institute
 
Ali Amin-Mansour
Research Funding - Novartis
 
Scott L. Carter
No Relationships to Disclose
 
Catherine Wu
Employment - Neon Therapeutics; Neon Therapeutics (I)
Leadership - Neon Therapeutics; Neon Therapeutics (I)
Stock and Other Ownership Interests - Neon Therapeutics; Neon Therapeutics (I)
Consulting or Advisory Role - Neon Therapeutics; Neon Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Neon Therapeutics; Neon Therapeutics (I)
 
Kwok-Kin Wong
No Relationships to Disclose
 
Chandrajit P. Raut
No Relationships to Disclose
 
Patrick Alexander Ott
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb
Research Funding - ARMO BioSciences; AstraZeneca; Bristol-Myers Squibb; Merck
 
Eliezer Mendel Van Allen
Consulting or Advisory Role - Roche; Syapse
 
George D. Demetri
Leadership - Blueprint Medicines
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; G1 Therapeutics; Kolltan Pharmaceuticals
Consulting or Advisory Role - ARIAD; Bayer; Bessor Pharma; Caris Life Sciences; Champions Oncology; Daiichi Sankyo; EMD Serono; G1 Therapeutics; Genocea Biosciences; Janssen Oncology; Kolltan Pharmaceuticals; Kyocera; Lilly; Nektar; Novartis; Pfizer; PharmaMar; Polaris; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Bayer (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Novartis (Inst)
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie (I)
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Novartis; Pfizer
Research Funding - ARIAD (Inst); Bayer (Inst); Blueprint Medicines (Inst); Novartis (Inst); Pfizer (Inst)